Immunocore has been awarded a Prix Galien UK award for KIMMTRAK, its treatment for metastatic uveal melanoma- a rare and aggressive form of eye cancer.
The Prix Galien UK is one of the highest accolades in the life sciences sector, recognising outstanding innovation and the development of treatments that deliver real clinical impact. Often described as the industry’s equivalent of the Nobel Prize, the award highlights the strength of the UK’s research and development capabilities.
KIMMTRAK is the first and only approved treatment for metastatic uveal melanoma, addressing a clear unmet need in cancer care. Its development and delivery mark a major milestone for patients and for Immunocore’s platform technology.
The award was accepted by Annelise Vuidepot, SVP, CTO, Research and UK Site Lead at Immunocore, who also serves as a Board member of Advanced Oxford. You can watch the video of the award presentation-
Read more about the awards ceremony and evening here.
